Catalyst Wire Dossier Catalyst Wire Dossier

89Zr-girentuximab

girentuximab · Telix Pharmaceuticals (Innovations) Pty Ltd
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for 89Zr-girentuximab, covering 2025-07-10 to 2026-01-07. Get the full timeline:

Most recent: Clinical Trial Update: Assessment of Safety, Tolerability, Radiation Dosimetry, Imaging Properties of 89Zr-girentuximab in Patients With NMIBC [EARLY_Phase 1]

See pricing